Drug Guru: a computer software program for drug design using medicinal chemistry rules
- PMID: 16870456
- DOI: 10.1016/j.bmc.2006.06.024
Drug Guru: a computer software program for drug design using medicinal chemistry rules
Abstract
Drug Guru (drug generation using rules) is a new web-based computer software program for medicinal chemists that applies a set of transformations, that is, rules, to an input structure. The transformations correspond to medicinal chemistry design rules-of-thumb taken from the historical lore of drug discovery programs. The output of the program is a list of target analogs that can be evaluated for possible future synthesis. A discussion of the features of the program is followed by an example of the software applied to sildenafil (Viagra) in generating ideas for target analogs for phosphodiesterase inhibition. Comparison with other computer-assisted drug design software is given.
Similar articles
-
Integrating medicinal chemistry, organic/combinatorial chemistry, and computational chemistry for the discovery of selective estrogen receptor modulators with Forecaster, a novel platform for drug discovery.J Chem Inf Model. 2012 Jan 23;52(1):210-24. doi: 10.1021/ci2004779. Epub 2011 Dec 15. J Chem Inf Model. 2012. PMID: 22133077
-
Molecular conceptor for training in medicinal chemistry, drug design, and cheminformatics.Chem Biol Drug Des. 2007 Jan;69(1):75-82. doi: 10.1111/j.1747-0285.2007.00465.x. Chem Biol Drug Des. 2007. PMID: 17313460
-
LEA3D: a computer-aided ligand design for structure-based drug design.J Med Chem. 2005 Apr 7;48(7):2457-68. doi: 10.1021/jm0492296. J Med Chem. 2005. PMID: 15801836
-
Optimizing the use of open-source software applications in drug discovery.Drug Discov Today. 2006 Feb;11(3-4):127-32. doi: 10.1016/S1359-6446(05)03692-5. Drug Discov Today. 2006. PMID: 16533710 Review.
-
Synthetic library design.Drug Discov Today. 2006 Aug;11(15-16):763-7. doi: 10.1016/j.drudis.2006.06.017. Drug Discov Today. 2006. PMID: 16846805 Review.
Cited by
-
Computational anti-COVID-19 drug design: progress and challenges.Brief Bioinform. 2022 Jan 17;23(1):bbab484. doi: 10.1093/bib/bbab484. Brief Bioinform. 2022. PMID: 34850817 Free PMC article. Review.
-
SCRIPDB: a portal for easy access to syntheses, chemicals and reactions in patents.Nucleic Acids Res. 2012 Jan;40(Database issue):D428-33. doi: 10.1093/nar/gkr919. Epub 2011 Nov 8. Nucleic Acids Res. 2012. PMID: 22067445 Free PMC article.
-
Guiding effective decisions: an interview with Matthew Segall, CEO of Optibrium. Interview by Wendy A. Warr.J Comput Aided Mol Des. 2011 Feb;25(2):103-6. doi: 10.1007/s10822-011-9411-7. Epub 2011 Jan 12. J Comput Aided Mol Des. 2011. PMID: 21225445 No abstract available.
-
A Role for Fragment-Based Drug Design in Developing Novel Lead Compounds for Central Nervous System Targets.Front Neurol. 2015 Sep 11;6:197. doi: 10.3389/fneur.2015.00197. eCollection 2015. Front Neurol. 2015. PMID: 26441817 Free PMC article. Review.
-
ALOHA: a novel probability fusion approach for scoring multi-parameter drug-likeness during the lead optimization stage of drug discovery.J Comput Aided Mol Des. 2013 Sep;27(9):771-82. doi: 10.1007/s10822-013-9679-x. Epub 2013 Oct 11. J Comput Aided Mol Des. 2013. PMID: 24113765
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources